<trans-title xml:lang="en"/>_West China Medical Journal

Authors：

, 

四川大學華西醫院腹部腫瘤科（成都??610041）;

Corresponding?author：

, Email: liujiyan1972@163.com

Keywords：

前列腺癌; 雄激素剝奪治療; 化學療法

DOI：

10.7507/1002-0179.201602014

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

前列腺癌是西方國家男性發病率排位第一的惡性腫瘤，近年來我國前列腺癌的發病率也呈逐漸上升趨勢。在晚期前列腺癌治療中雄激素剝奪治療成為首選和最重要的治療措施，但大部分前列腺癌患者最終會進展為去勢抵抗性前列腺癌。因此，研究者們一直在尋找在雄激素剝奪治療基礎上可以聯用的方法以提高療效。2004 年，多西他賽被證明是第 1 個能改善晚期去勢抵抗性前列腺癌患者生存的化學療法藥物。這樣的結果使研究者們發起了多個多西他賽聯合雄激素剝奪治療晚期前列腺癌的臨床研究。該文就這些相關臨床研究及最新進展作了綜述。

Citation： 蔡忠, 劉繼彥. . West China Medical Journal, 2017, 32(2): 282-285. doi: 10.7507/1002-0179.201602014 Copy

1.	?Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 2012, 61(6): 1079-1092.
2.	Cullen J, Elsamanoudi S, Brassell SA, et al. The burden of prostate cancer in Asian nations. J Carcinog, 2012, 11(11): 7.
3.	Sweeney C, Carducci MA, Eisenberger MA, et al. Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol, 2014, 32(5S): Abstr 7560.
4.	Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol, 2013, 14(2): 149-158.
5.	Wu JN, Fish KM, Evans CP, et al. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-Year period. Cancer, 2014, 120(6): 818-823.
6.	Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502-1512.
7.	Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study. J Clin Oncol, 2008, 26(2): 242-245.
8.	Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-1520.
9.	Sweeney C, Chen YH, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase Ⅲ randomized trial. J Clin Oncol, 2014, 32(5S): Abstr LBA2.
10.	James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol, 2015, 67(6): 1028-1038.
11.	Murphy P, Beckley S, Brady F, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer, 1983, 51(7): 1264-1272.
12.	Murphy P, Huben P, Priore R. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology, 1986, 28(1): 36-40.
13.	Osborne CK, Blumestein B, Crawford ED, et al. Combined versus se-quential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol, 1990, 8(10): 1675-1682.
14.	Pummer K, Lehnert M, Stettner H, et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol, 1997, 32(Suppl 3): 81-85.
15.	Janknegt RA, Bloon TA, Van De Beek C, et al. Combined hormono/che-motherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The dutch estracyt study group. Urology, 1997, 49(3): 411-420.
16.	Boel K, Van Poppel H, Goethuys H, et al. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial. Anticancer Res, 1999, 19(3B): 2157-2161.
17.	De Reijke TM, Keuppens FI, Whelan P, et al. Orchiectomy and orchiec-tomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European organization for re-search in cancer therapy genitourinary group trial. J Urol, 1999, 162(5): 1658-1664.
18.	Kuriyama M, Takahashi Y, Sahashi M, et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol, 2001, 31(1): 18-24.
19.	Noguchi M, Noda S, Yoshida M, et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol, 2004, 11(2): 103-109.
20.	Millikan E, Wen S, Pagliaro C, et al. Phase Ⅲ trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol, 2008, 26(36): 5936-5942.
21.	Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res, 2014, 74(8): 2270-2282.
22.	Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic Non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol, 2016, 70(2): 256-262.

1. ?Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 2012, 61(6): 1079-1092.
2. Cullen J, Elsamanoudi S, Brassell SA, et al. The burden of prostate cancer in Asian nations. J Carcinog, 2012, 11(11): 7.
3. Sweeney C, Carducci MA, Eisenberger MA, et al. Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol, 2014, 32(5S): Abstr 7560.
4. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol, 2013, 14(2): 149-158.
5. Wu JN, Fish KM, Evans CP, et al. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-Year period. Cancer, 2014, 120(6): 818-823.
6. Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502-1512.
7. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study. J Clin Oncol, 2008, 26(2): 242-245.
8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-1520.
9. Sweeney C, Chen YH, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase Ⅲ randomized trial. J Clin Oncol, 2014, 32(5S): Abstr LBA2.
10. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol, 2015, 67(6): 1028-1038.
11. Murphy P, Beckley S, Brady F, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer, 1983, 51(7): 1264-1272.
12. Murphy P, Huben P, Priore R. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology, 1986, 28(1): 36-40.
13. Osborne CK, Blumestein B, Crawford ED, et al. Combined versus se-quential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol, 1990, 8(10): 1675-1682.
14. Pummer K, Lehnert M, Stettner H, et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol, 1997, 32(Suppl 3): 81-85.
15. Janknegt RA, Bloon TA, Van De Beek C, et al. Combined hormono/che-motherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The dutch estracyt study group. Urology, 1997, 49(3): 411-420.
16. Boel K, Van Poppel H, Goethuys H, et al. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial. Anticancer Res, 1999, 19(3B): 2157-2161.
17. De Reijke TM, Keuppens FI, Whelan P, et al. Orchiectomy and orchiec-tomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European organization for re-search in cancer therapy genitourinary group trial. J Urol, 1999, 162(5): 1658-1664.
18. Kuriyama M, Takahashi Y, Sahashi M, et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol, 2001, 31(1): 18-24.
19. Noguchi M, Noda S, Yoshida M, et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol, 2004, 11(2): 103-109.
20. Millikan E, Wen S, Pagliaro C, et al. Phase Ⅲ trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol, 2008, 26(36): 5936-5942.
21. Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res, 2014, 74(8): 2270-2282.
22. Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic Non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol, 2016, 70(2): 256-262.

West China Medical Journal

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content